Genus PLC Board Changes (9433S)
March 22 2021 - 3:00AM
UK Regulatory
TIDMGNS
RNS Number : 9433S
Genus PLC
22 March 2021
For Immediate Release
22 March 2021
Genus plc
('Genus', or the 'Company')
Board Changes
Non-Executive Director Retirement and Appointment
Genus (LSE: GNS), a leading global animal genetics company,
announces that Professor Ian Charles has informed the Company of
his intention to step down and retire from the Genus Board,
effective from 31 May 2021. Professor Charles has served as a
Non-Executive Director and advisor to the Genus Portfolio Steering
Committee ('GPSC') for over three years.
Genus is also pleased to announce the appointment of Professor
Jason Chin to the Board as a Non-Executive Director, with effect
from 1 April 2021. Professor Chin will become the Board's advisor
to the GPSC upon Professor Charles' retirement.
Professor Chin is the Head of the Centre for Chemical and
Synthetic Biology at the Medical Research Council Laboratory for
Molecular Biology in Cambridge, where he works across disciplines
to develop and apply methods for reprogramming the genetic code of
living organisms. His research spans Chemistry, Chemical Biology
and Synthetic Biology, and he holds Associate Faculty status at the
Wellcome Sanger Institute where he researches synthetic genomics.
He is a fellow of Trinity College, Cambridge and a Fellow of the
Academy of Medical Sciences. Professor Chin brings a developed
understanding of scientific advisory work and has sat on the
scientific advisory boards of a number of companies, including
Synaffix BV and Orbit Discovery Limited, where he retains an
advisory role.
Commenting on the changes, Iain Ferguson, Chair of Genus,
said:
"Over his tenure Ian has provided the Company with significant
scientific expertise, guidance and insight as the Company has
progressed its strategic focus on research and development in
genomics, gene editing and biosystems engineering. We thank Ian for
his significant contributions during that time and are delighted to
welcome to the Board Jason Chin, whose deep scientific expertise
and experience will enable the Board to have a seamless transition
as we continue to execute our strategy."
Genus Tel: +44(0)1256
345970
Iain Ferguson, Chair
Stephen Wilson, Chief Executive
Buchanan Tel: +44(0)207 466
5000
Charles Ryland /Chris Lane
This announcement is available on the Genus website
www.genusplc.com
About Genus
Genus is a world-leading animal genetics company. Genus creates
advances to animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming
and food producers. Its technology is applicable across livestock
species and is currently commercialised by Genus in the dairy, beef
and pork food production sectors.
Genus's worldwide sales are made in over seventy-five countries
under the trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs)
and comprise semen, embryos and breeding animals with superior
genetics to those animals currently in farms. Genus's customers'
animals produce offspring with greater production efficiency, and
quality, and use these to supply the global dairy and meat supply
chains.
The Group's competitive edge has been created from the ownership
and control of proprietary lines of breeding animals, the
biotechnology used to improve them and its global supply chain,
technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus
companies operate in over twenty-five countries on six continents,
with research laboratories located in Madison, Wisconsin, USA.
Regulatory Notes
Details of any payments to be made to Jason Chin will be
disclosed in full in the Company's 2021 Directors' Remuneration
Report. Any such terms will be consistent with the Company's
approved Directors' Remuneration Policy.
This announcement is made in accordance with Listing Rule
9.6.11R. There are no matters to be disclosed in connection with
Listing Rule 9.6.13R (2) - (6). The person responsible for making
this announcement on behalf of the Group is Dan Hartley (General
Counsel and Company Secretary).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAPPUWGWUPGGBG
(END) Dow Jones Newswires
March 22, 2021 03:00 ET (07:00 GMT)
Genus (LSE:GNS)
Historical Stock Chart
From Apr 2024 to May 2024
Genus (LSE:GNS)
Historical Stock Chart
From May 2023 to May 2024